赫赛汀对吉非替尼诱导肺癌A549细胞凋亡的影响

Effect of trastuzumab(herceptin) on the apoptosis induced by ZD1839(iressa) in lung cancer A549 cells

目的:研究吉非替尼与赫赛汀联合应用对人肺腺癌A549细胞凋亡的影响。方法:应用MTT法,流式细胞仪Annexin V-PI双标法、DAPI荧光染色等多项方法,体外研究吉非替尼与赫赛汀联合对A549细胞的促凋亡作用。结果:吉非替尼与赫赛汀单独应用及联合应用均可以明显抑制人肺腺癌A549细胞的生长,促进细胞凋亡,并呈浓度及时间依赖性,2者联合作用人肺腺癌A549细胞24h、48h、72h的凋亡率显著高于单用吉非替尼或赫赛汀组(P<0.05),2者呈现出相加的抗瘤效果。结论:吉非替尼与赫赛汀联合应用在体外对人肺腺癌A549细胞有明显的促凋亡作用。

AIM： ZD1839 and trastuzumab are reported to improve the therapeutic efficacy of treatment for non-smallcell lung cancer （NSCLC） and breast cancer, respectively, although the effectiveness of either drug alone is not satisfactory. NSCLC cells often express both EGFR and HER2. We therefore investigated whether a combination of ZD1839 and trastuzumab had an additive or synergistic antitumor effect. METHODS： MTT was used to measure the inhibitory effects of ZD1839 （iressa） and trastuzumab （herceptin） on the growth of A549 cells. The cell apoptosis was studied by DAPI staining, and Annexin V/PI double labeling. RESULTS： The inhibitory action of cell growth was seen in A549 cells dealing with ZD1839 and trastuzumab. They inhibited the growth of the human lung cancer cell line A549 in a concentration and time dependent manners. Compared with either ZD1839 or trastuzumab alone, combination with cureumin respectively increased the growth inhibition rate and increased apoptosis of A549 cells （ P 〈 0. 05 ） significantly, suggesting the synergistic actions of the two drugs. CONCLUSION： The results suggest that combination treatment with ZD1839 and trastuzumab might have improved therapeutic efficacy against NSCLC cells expressing both EGFR and HER2.